Form 4: Praxis Precision Medicines Director Granted Stock Options Valued at $44.04 Per Share

Praxis Precision Medicines, Inc. Director William D. Young was granted 10,520 stock options with an exercise price of $44.04, vesting over one year starting June 26, 2025.

Summary

• William D. Young, a Director of Praxis Precision Medicines, Inc. (PRAX), was granted 10,520 stock options.
• The stock options have an exercise price of $44.04 per share.
• The options were granted on June 26, 2025, which is also the commencement date for vesting.
• The shares subject to this option will vest in twelve equal monthly installments over a one-year period.
• The expiration date for these stock options is June 26, 2035.
• Following this transaction, Mr. Young beneficially owns 10,520 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a standard compensation practice, aligning the director's interests with long-term company performance. This is generally viewed as a neutral to slightly positive event as it incentivizes leadership.

Positives

• The grant of stock options to a director aligns their financial interests with the long-term performance and shareholder value creation of Praxis Precision Medicines, Inc.
• Equity-based compensation is a standard practice that incentivizes directors to contribute to the company's growth and success.

Negatives

• No negative information is typically disclosed in a Form 4 filing, which primarily reports insider transactions and compensation events.

Risks

• No specific risks are detailed in this Form 4 filing, as it is a transactional disclosure document focused on insider ownership changes rather than comprehensive risk factors.

Future Outlook

The vesting schedule indicates that the 10,520 stock options will become exercisable in monthly installments over the next year, commencing June 26, 2025, allowing the director to potentially acquire common stock in the future.

Industry Context

The grant of stock options to directors is a common and widely accepted practice within the biotechnology and pharmaceutical industries, serving as a key component of executive and board compensation packages. This practice aims to align the interests of company leadership with those of shareholders by tying compensation to the company's stock performance.

Comparison to Industry Standards

• Stock option grants are a common form of executive and director compensation across the biotechnology and pharmaceutical industries, aiming to align leadership incentives with shareholder value creation.
• The vesting schedule of 12 equal monthly installments over one year is a standard approach to ensure continued commitment and performance.
• Without specific peer compensation data for comparable companies in the biotech sector, a direct quantitative comparison of the grant size or exercise price relative to industry benchmarks is not feasible from this document alone.

Related Party Transactions

• The grant of stock options to William D. Young, a director of Praxis Precision Medicines, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant aims to align the director's interests with shareholder value, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this specific filing.
• Management: The director receives equity-based compensation, which is a key component of their overall remuneration package.

Next Steps

• The stock options will vest in twelve equal monthly installments over one year, commencing on June 26, 2025.

Key Dates

Keywords

Praxis Precision Medicines, PRAX, Stock Option, Director Compensation, Insider Transaction, Equity Grant, SEC Form 4, Beneficial Ownership